logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
B

Burt Nabors

university of alabama at birmingham
H指数:68
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

UPDATED RESULTS OF PHASE 3 STELLAR TRIAL: EFLORNITHINE IMPROVES OVERALL SURVIVAL AND BLINDED INDEPENDENT CENTRAL REVIEW DETERMINED PROGRESSION FREE SURVIVAL IN PATIENTS WITH RECURRENT WHO 2021 GRADE 3 IDH-MUTANT ASTROCYTOMA

更新后的III期STELLAR试验结果：依氟鸟氨酸改善2021年WHO分级3级IDH突变型星形细胞瘤患者的总生存期和盲态独立中央审查确定的无进展生存期

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Colman, Howard; Lombardi, Giuseppe; Wong, Eric; Walbert, Tobias; Eoli, Marica; Lassman, Andrew; Peereboom, David; Kizilbash, Sani; Kamiya-Matsuoka, Carlos; Pitz, Marshall; Strowd, Roy; Desjardins, Annick; Kumthekar, Priya; Mason, Warren; Pellerino, Alessia; Soffietti, Riccardo; Butowski, Nicholas; Forsyth, Peter; Hamza, Mohamed; Hau, Peter; Lallana, Enrico; Nabors, Burt; Piccioni, David; Uhlmann, Erik; Welsh, Liam; Wen, Patrick; Dietrich, Jorg; Levin, Victor
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2，异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者中，体素（3D）评估相较于传统双向（2D）评估在INDIGO III期试验中的比较

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率（TGR）建模预测了在INDIGO三期试验中，接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变（mIDH1/2）胶质瘤患者的临床结局。

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Ellingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

Vorasidenib在IDH1突变或IDH2突变低级别胶质瘤（INDIGO）：一项随机、双盲、安慰剂对照、III期试验的次要和探索性终点

The Lancet Oncology
IF0
2025-10-290
PRE
Timothy F Cloughesy; Martin J van den Bent; Mehdi Touat; Deborah T Blumenthal; Katherine B Peters; Benjamin M Ellingson; Jennifer L Clarke; Joe Mendez; Shlomit Yust-Katz; Liam Welsh; Warren P Mason; Francois Ducray; Yoshie Umemura; Burt Nabors; Matthias Holdhoff; Andreas F Hottinger; Yoshiki Arakawa; Juan M Sepulveda; Wolfgang Wick; Riccardo Soffietti; James Perry; Pierre Giglio; Macarena de la Fuente; Elizabeth Maher; Andrew Bottomley; Adriana E Tron; Denise Yi; Dan Zhao; Shuchi S Pandya; Lori Steelman; Islam Hassan; Patrick Y Wen; Ingo K Mellinghoff
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas

I期/II期和机会窗口研究：帕米帕利布与常规替莫唑胺联合治疗异柠檬酸脱氢酶突变型胶质瘤的复发病例

Neuro-Oncology
IF13.4
2025-10-160
PRE
David Schiff; Xiaobu Ye; Jing Li; Benjamin M Ellingson; Patrick Y Wen; Tobias Walbert; Jian Campian; Louis B Nabors; Byram H Ozer; Arati Desai; Antonio Omuro; Serena Desideri; Neeraja Danda; Stuart Grossman; Ranjit S Bindra
EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

早期肿瘤体积变化预测Midh1/2胶质瘤的临床结局：INDIGO III期试验的事后分析结果

NEURO-ONCOLOGY
IF13.4
2025-10-010
OAAI
Ellingson, B. M.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Welsh, L.; Mason, W. P.; Ducray, F.; Umemura, Y.; Nabors, B.; Holdhoff, M.; Hottinger, A. F.; Arakawa, Y.; Sepulveda, J. M.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Zhao, D.; Pandya, S. S.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.

研究方向

暂未获取到该数据
P
Patrick Y. Wen
H 指数:145论文数:1,930被引数:8.6万
M
Michael Weller
H 指数:175论文数:2,841被引数:16.4万
S
Stuart A. Grossman
H 指数:75论文数:626被引数:2.0万
M
Matthias Holdhoff
H 指数:42论文数:328被引数:1.8万
R
Roger Stupp
H 指数:114论文数:841被引数:9.1万
D
David A. Reardon
H 指数:119论文数:1,223被引数:6.2万
J
James M. Markert
H 指数:55论文数:372被引数:1.2万
P
Peter H. King
H 指数:43论文数:176被引数:7,415
M
Martin J. van den Bent
H 指数:128论文数:1,361被引数:9.9万
T
Timothy F. Cloughesy
H 指数:128论文数:1,355被引数:6.2万